Ferriprox Approved to Treat 'Iron Overload'10/14/11
FRIDAY, Oct. 14 (HealthDay News) -- Ferriprox (deferiprone) has
been approved by the U.S. Food and Drug Administration to treat
excess blood iron among people who require frequent
People with the genetic blood disorder thalessemia have an
insufficient supply of hemoglobin, the protein that helps deliver
oxygenated blood throughout the body. They often need frequent
blood transfusions, which may lead to a buildup of iron in the
blood (iron overload). People with thalessemia also are at
greater-than-average risk of developing liver disease, diabetes,
arthritis, heart failure or an abnormal heart rhythm, the FDA said
in a news release.
Ferriprox has been approved for use in cases where other methods
to remove excess iron are insufficient, the agency said.
In clinical testing of the drug, the most common side effects
noted were nausea, vomiting, abdominal and joint pain, discolored
urine, a potentially deadly decrease in infection-fighting white
blood cells, and an increase in a liver enzyme that may indicate
tissue or liver damage.
As a condition of approval, the Toronto-based drug maker
ApoPharma must study the use of Ferriprox among people with iron
overload who also have sickle cell disease, the FDA said.
The U.S. Centers for Disease Control and Prevention has more
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.